First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)
Blood(2021)
Abstract
BACKGROUND: CD19 targeted chimeric antigen receptor (CAR) T cells are a transformative treatment option for patients with relapsed, refractory B cell malignancies. Despite remarkable responses in heavily pretreated patients, challenges remain related to toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), along with relapse related to tumor antigen loss.
MoreTranslated text
Key words
cd19,clbr001,cell
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined